Cardinal Health reported a better-than-expected quarter for fiscal 2027, with revenue of $67.51 billion, up 4%, and adjusted earnings per share of $3.26, an increase of 28%. The company raised its full-year adjusted earnings per share guidance to $12.80-$13.00 and strengthened its outlook for the Pharmaceutical and Specialty Solutions and Other segments, while Global Medical Products and Distribution was hurt by tariffs and higher petroleum costs. The specialty pharmaceuticals business grew by more than 17%, led by urology and oncology, and Cardinal Health has completed nearly two-thirds of its enterprise contract renewals over the past 12 months. Shares rose more than 3% on Thursday before the analyst trimmed 50 shares, and he raised his price target from $265 to $300 per share while maintaining a hold-equivalent rating.
Source: Read the original article
